Literature DB >> 28515095

Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma.

Hiroo Katsuya1,2, Mototsugu Shimokawa3, Kenji Ishitsuka1,4, Kazuhiro Kawai5, Masahiro Amano6, Atae Utsunomiya7, Ryosuke Hino8, Shuichi Hanada9, Tatsuro Jo10, Kunihiro Tsukasaki11, Yukiyoshi Moriuchi12, Eisaburo Sueoka13, Shinichiro Yoshida14, Hitoshi Suzushima15, Masaharu Miyahara16, Kiyoshi Yamashita17, Tetsuya Eto18, Junji Suzumiya19, Kazuo Tamura1.   

Abstract

Adult T-cell leukemia-lymphoma (ATL) has been divided into 4 clinical subtypes: acute, lymphoma, chronic, and smoldering. The aim of this study is to develop a novel prognostic index (PI) for chronic and smoldering ATL. We conducted a nationwide retrospective survey on ATL patients, and 248 fully eligible individuals were used in this analysis. In the univariate analysis, sex, performance status, log10 (soluble interleukin-2 receptor [sIL-2R]), neutrophils count, and lymphadenopathy showed values of P < .05 in training samples. A multivariate analysis was performed on these factors, and only log10 (sIL-2R) was identified as an independent prognostic factor in training samples. Using a regression coefficient of this variable, a prognostic model was formulated to identify different levels of risk: indolent ATL-PI (iATL-PI) = 1.51 × log10 (sIL-2R [U/mL]). The values calculated by iATL-PI were divided into 3 groups using a quartile point. In the validation sample, median survival times (MSTs) were 1.6 years, 5.5 years, and not reached for patients in the high-, intermediate-, and low-risk groups, respectively (P < .0001). To make the scoring system clinically practicable, we simplified iATL-PI according to trichotomizing sIL-2R at 1000 and 6000 U/mL, using a quartile point. Patients with more than 6000 U/mL sIL-2R were categorized into the high-risk group, less than and equal to 1000 U/mL into the low-risk group, and the others into the intermediate-risk group, and MSTs were 1.6 years, not reached, and 5.5 years, respectively (P < .0001). iATL-PI has potential as a novel tool for a risk-adapted therapeutic approach.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28515095     DOI: 10.1182/blood-2017-01-757542

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

Review 1.  Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia/lymphoma in Japan.

Authors:  Hiroaki Miyoshi; Koichi Ohshima
Journal:  Int J Hematol       Date:  2018-03-03       Impact factor: 2.490

2.  Clinicogenetic risk modeling in ATL.

Authors:  Noriaki Yoshida; David M Weinstock
Journal:  Blood       Date:  2018-01-11       Impact factor: 22.113

Review 3.  Topics on the molecular pathogenesis and therapeutic approaches for T/NK-cell lymphoma.

Authors:  Motoko Yamaguchi
Journal:  J Clin Exp Hematop       Date:  2017

4.  Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.

Authors:  Lucy B Cook; Shigeo Fuji; Olivier Hermine; Ali Bazarbachi; Juan Carlos Ramos; Lee Ratner; Steve Horwitz; Paul Fields; Alina Tanase; Horia Bumbea; Kate Cwynarski; Graham Taylor; Thomas A Waldmann; Achilea Bittencourt; Ambroise Marcais; Felipe Suarez; David Sibon; Adrienne Phillips; Matthew Lunning; Reza Farid; Yoshitaka Imaizumi; Ilseung Choi; Takashi Ishida; Kenji Ishitsuka; Takuya Fukushima; Kaoru Uchimaru; Akifumi Takaori-Kondo; Yoshiki Tokura; Atae Utsunomiya; Masao Matsuoka; Kunihiro Tsukasaki; Toshiki Watanabe
Journal:  J Clin Oncol       Date:  2019-01-18       Impact factor: 44.544

5.  Phosphorylated STAT3 expression predicts better prognosis in smoldering type of adult T-cell leukemia/lymphoma.

Authors:  Kazuho Morichika; Kennosuke Karube; Hirona Kayo; Shuta Uchino; Yukiko Nishi; Sawako Nakachi; Shiki Okamoto; Satoko Morishima; Kazuiku Ohshiro; Iwao Nakazato; Takuya Fukushima; Hiroaki Masuzaki
Journal:  Cancer Sci       Date:  2019-07-23       Impact factor: 6.716

6.  CD4+ CADM1+ cell percentage predicts disease progression in HTLV-1 carriers and indolent adult T-cell leukemia/lymphoma.

Authors:  Junya Makiyama; Seiichiro Kobayashi; Eri Watanabe; Tomohiro Ishigaki; Toyotaka Kawamata; Makoto Nakashima; Makoto Yamagishi; Kazumi Nakano; Arinobu Tojo; Toshiki Watanabe; Kaoru Uchimaru
Journal:  Cancer Sci       Date:  2019-12       Impact factor: 6.716

Review 7.  Comprehensive genomic analysis identifying heterogeneity in peripheral T-cell lymphoma.

Authors:  Noriaki Yoshida; Kyohei Yamada; Koichi Ohshima
Journal:  Cancer Sci       Date:  2021-02-25       Impact factor: 6.716

Review 8.  Maintenance of long remission in adult T-cell leukemia by Tax-targeted vaccine: A hope for disease-preventive therapy.

Authors:  Mari Kannagi; Atsuhiko Hasegawa; Yoshiko Nagano; Tadafumi Iino; Jun Okamura; Youko Suehiro
Journal:  Cancer Sci       Date:  2019-02-19       Impact factor: 6.716

Review 9.  Biomarkers and Preclinical Models for Adult T-Cell Leukemia-Lymphoma Treatment.

Authors:  Lee Ratner
Journal:  Front Microbiol       Date:  2019-09-18       Impact factor: 5.640

10.  Prognostic significance of plasma IL-2 and sIL-2Rα in patients with first-ever ischaemic stroke.

Authors:  Haiping Zhao; Fangfang Li; Yuyou Huang; Sijia Zhang; Lingzhi Li; Zhenhong Yang; Rongliang Wang; Zhen Tao; Ziping Han; Junfen Fan; Yangmin Zheng; Qingfeng Ma; Yumin Luo
Journal:  J Neuroinflammation       Date:  2020-08-14       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.